Roller-coaster ride for Sarepta after ‘erroneous’ adverse event report

Sarepta found itself needing to set the record straight Thursday after an adverse event report for its DMD gene therapy sent shares down by as much as $27.26 (19%) to $115.

According to the report filed with

Read the full 364 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE